Pregabalin Capsule
Product Images NDC 72162-2304

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-2304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622304)

This is a product label for Pregabalin capsules containing 150 mg each. The storage instructions advise keeping the capsules at 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). The label emphasizes the importance of storing the medication in a tight, child-resistant container and keeping it out of reach of children. For more information on dosage and medication guidance, refer to the provided website link.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

This text appears to be a formula used for calculating the estimated glomerular filtration rate (eGFR) based on serum creatinine levels and weight. The formula seems to involve multiplying the weight in kilograms by the serum creatinine level in mg/dL. For female patients, the result is then multiplied by a coefficient of 0.85. This formula might be used in the medical field to assess kidney function.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

This text includes information regarding the improvement of patients' parents. It mentions the use of Pregabalin at different dosages and a placebo. It also references pain improvement from baseline.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

This text provides a comparison of the effectiveness of Fregabalin 100mg three times a day, Pregabalin 80mg three times a day, and Placebo in improving pain in patients. The table shows the number of patients improved with each treatment and the percentage improvement in pain from baseline. This data can be used to evaluate the efficacy of these treatments for pain management.*

FDA Label Image

Pregabalin-fig-06 (Pregabalin Fig 06)

FDA Label Image

Pregabalin-fig-07 (Pregabalin Fig 07)

FDA Label Image

Pregabalin-fig-08 (Pregabalin Fig 08)

This text provides percentage values for responder rates associated with different dosages in a study. The study includes a placebo, 2.5 mg/kg/day, and 10 mg/kg/day dosages, with responder rates indicated.*

FDA Label Image

Pregabalin-fig-09 (Pregabalin Fig 09)

The text provided seems to show dosage information for different medications, including Pregabalin at 100mg and 450mg daily doses, and a placebo. It also includes a chart with the percent improvement in pain from baseline for the medications.*

FDA Label Image

Pregabalin-fig-10 (Pregabalin Fig 10)

Estimated % Subjects without LTR: 0%, 0%, 20%, 10%, 0%. The data seems to involve a comparison between Pregabain and a Placebo over 12 days of the study.*

FDA Label Image

Pregabalin-fig-11 (Pregabalin Fig 11)

FDA Label Image

Pregabalin-fig-12 (Pregabalin Fig 12)

This description provides data on the percentage of subjects improved, with numbers ranging from 100 to 280. It also mentions the percentage improvement from baseline to Week 16 for Pregabalin and Placebo. This information can be helpful in evaluating the effectiveness of the treatments being tested.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.